Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation ...

Rezpegaldesleukin, an investigational interleukin-pathway agonist, demonstrated efficacy and safety for people with moderate to severe atopic dermatitis, meeting its primary and secondary ...

Interleukin-2 inhibits FMS-like tyrosine kinase 3 receptor ligand (flt3L)-dependent development and function of conventional and plasmacytoid dendritic cells Annie W. Lau-Kilby, Cosima C. Kretz, ...

Cardiovascular disease (CVD) remains a major health burden despite significant therapeutic advances accomplished over the last decades. It is widely and increasingly recognized that systemic ...

REZOLVE-AD, the phase 2b study, is set to investigate the efficacy and safety of rezpegaldesleukin, a first-in-class interleukin-2 receptor agonist that proliferates and activates regulatory T ...

On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer’s Disease. The data was shared ...

GlobalData’s report assesses the drugs in the Interleukin 2 Receptor Subunit Beta pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development ...

Low dose interleukin 2 is being tested as an immunomodulatory approach in neurodegenerative diseases. It increases the number and activity of regulatory T cells (Tregs) that suppress inflammation. At ...